Tradestie Institutional Equity Comparison Engine
SRZN vs CRBP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (3โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus CRBP at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against CRBP sits in BREAKDOWN (66th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SRZN N/M vs CRBP N/M Fwd P/E
Growth & Margin Winner
SRZN
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs -100.0%
Momentum & Technical Winner
SRZN
1Y +166.7% vs -69.5% ยท 52W Pos 79% vs 6%
Options & Structure Winner
SRZN
CONSOLIDATION (5th %ile IV) vs BREAKDOWN (66th %ile IV)
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.32
+2.25% 1D
Market Cap
$602.5M
1M Return
+37.88%
1Y Return
+166.67%
Forward P/E
N/M
Unified AI Score
34.3 / 100
SELL
Tech 5.0
Fund 32.0
Flow 65.0
Mom 40.0
CRBP
NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap
$69.9M
1M Return
-25.33%
1Y Return
-69.51%
Forward P/E
N/M
Unified AI Score
45.0 / 100
HOLD
Tech 43.0
Fund 54.0
Flow 69.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SRZN +166.67%
CRBP -69.51%
Spread: +236.18 pp (SRZN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRZN Revenue | CRBP Revenue | SRZN Op. Margin | CRBP Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2017 | N/A | $0M | N/A | -1334.4% | CRBP |
| FY2018 | N/A | $0M | N/A | -1176.8% | CRBP |
| FY2019 | N/A | $40M | N/A | -213.3% | CRBP |
| FY2020 | N/A | $0M | N/A | -3119.2% | CRBP |
| FY2021 | N/A | $0M | N/A | -6350.1% | CRBP |
| FY2022 | $10M | N/A | -354.7% | N/A | SRZN |
| FY2024 | $10M | N/A | -239.7% | N/A | SRZN |
| FY2025 | $0M | N/A | -1210.6% | N/A | SRZN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRZN | CRBP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $602.5M | $69.9M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +408.6% | -100.0% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | -485.4% | 0.0% | Higher Margin | CRBP |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -62.8% | -131.5% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 79% ($12โ$38) | 6% ($3โ$13) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 1.21ฮฒ ยท 62% Vol | 1.93ฮฒ ยท 121% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 34.3 / 100 (SELL) | 45.0 / 100 (HOLD) | Higher Composite | CRBP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SRZN vs CRBP Buy Guide
SRZN
CONSOLIDATION
37d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
CRBP
BREAKDOWN
58d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
66th %ile
IV Regime
Elevated (60thโ80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SRZN nor CRBP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.